Medtronic

Medtronic

Overview

Medtronic is an American Irish-domiciled medical device company headquartered in Dublin, Ireland, with operational headquarters in Minneapolis, Minnesota. Founded in 1949, Medtronic is the world's largest medical device company and a pioneer in deep brain stimulation (DBS) for movement disorders including [Parkinson's disease](/diseases/parkinsons-disease) and essential tremor[@medtronic2024].

Company Overview

| Attribute | Details |
|-----------|---------|
| Ticker | NYSE: MDT |
| Headquarters | Dublin, Ireland (operational: Minneapolis, MN) |
| Founded | 1949 |
| CEO | Geoff Martha (since 2020) |
| Employees | ~95,000 |
| Market Cap | ~$110 billion (2024) |
| Revenue | ~$32 billion (FY2024) |

Deep Brain Stimulation Systems

Activa Family

Medtronic's primary DBS product line is the Activa family:

Activa PC

• Description: Primary cell-based neurostimulator
• Electrode Contacts: 4 contacts (Medtronic 3387/3389 leads)
• Programming: Standard programming with directional capability via certain leads
• Battery: Rechargeable (typical life: 5-15 years)

Activa RC

• Description: Rechargeable neurostimulator
• Advantages: Smaller size, longer battery life (up to 15 years)
• Charging: Patient-controlled inductive charging

Activa S

• Description: Most advanced DBS system with sensing capabilities
• Brain Sensing: Can record local field potentials (LFP)
• Closed-Loop: Adaptive DBS capabilities (research use)

DBS Leads

...

Medtronic

Overview

Medtronic is an American Irish-domiciled medical device company headquartered in Dublin, Ireland, with operational headquarters in Minneapolis, Minnesota. Founded in 1949, Medtronic is the world's largest medical device company and a pioneer in deep brain stimulation (DBS) for movement disorders including [Parkinson's disease](/diseases/parkinsons-disease) and essential tremor[@medtronic2024].

Company Overview

| Attribute | Details |
|-----------|---------|
| Ticker | NYSE: MDT |
| Headquarters | Dublin, Ireland (operational: Minneapolis, MN) |
| Founded | 1949 |
| CEO | Geoff Martha (since 2020) |
| Employees | ~95,000 |
| Market Cap | ~$110 billion (2024) |
| Revenue | ~$32 billion (FY2024) |

Deep Brain Stimulation Systems

Activa Family

Medtronic's primary DBS product line is the Activa family:

Activa PC

• Description: Primary cell-based neurostimulator
• Electrode Contacts: 4 contacts (Medtronic 3387/3389 leads)
• Programming: Standard programming with directional capability via certain leads
• Battery: Rechargeable (typical life: 5-15 years)

Activa RC

• Description: Rechargeable neurostimulator
• Advantages: Smaller size, longer battery life (up to 15 years)
• Charging: Patient-controlled inductive charging

Activa S

• Description: Most advanced DBS system with sensing capabilities
• Brain Sensing: Can record local field potentials (LFP)
• Closed-Loop: Adaptive DBS capabilities (research use)

DBS Leads

Medtronic offers multiple lead configurations:

• 3387: 4-contact, 1.5mm spacing, 10.5mm contact length
• 3389: 4-contact, 0.5mm spacing, 1.5mm contact length (for precise targeting)
• 3391: Directional lead with 8 contacts (3 directional segments)

Clinical Evidence

Parkinson's Disease

Medtronic DBS is the most extensively studied treatment for Parkinson's disease motor symptoms:

Key Trials

EARLYSTIM Trial

• Finding: DBS + medical therapy superior to medical therapy alone in patients with early motor complications
• Result: 26% improvement in quality of life (PDQ-39) vs. -1% in control
• Published: Schuepbach et al., NEJM 2013

VA Cooperative Study

• Finding: DBS + medical therapy superior to medical therapy alone
• Result: 41% improvement in off medication motor scores vs. baseline
• Published: Weaver et al., JAMA 2009

Essential Tremor

Medtronic DBS is FDA-approved for essential tremor:

• Target: Vim nucleus of the thalamus
• Outcome: 50-80% reduction in tremor amplitude
• Published: Ondo et al., Neurology 2006

Dystonia

DBS is approved for dystonia, with significant improvements in:

• Motor function
• Pain reduction
• Quality of life

Future Indications

Medtronic is investigating DBS for:

• Epilepsy: Responsive neurostimulation (separate NeuroPace product)
• Depression: Major depressive disorder (clinical trials)
• Obsessive-Compulsive Disorder: OCD (humanitarian device exemption)

Competitive Landscape

Medtronic competes in the DBS market with:

| Company | Product | FDA Status | Key Features |
|---------|---------|------------|--------------|
| Abbott Laboratories | Infinity DBS | Approved (2016) | Directional leads, small IPG |
| Boston Scientific | Vercise DBS | Approved (2017) | AI navigation, multiple current sources |

Medtronic maintains the largest market share in DBS (>60%).

Regulatory History

| Year | Event |
|------|-------|
| 1997 | FDA approves Medtronic DBS for essential tremor |
| 2002 | FDA approves DBS for Parkinson's disease |
| 2015 | FDA approves Activa PC + S for Parkinson's, dystonia, epilepsy |
| 2018 | FDA approves directional leads |
| 2023 | FDA approves Percept PC with brain sensing |

Treatment Statistics

• Patients Treated: >150,000 patients worldwide since 1997
• Implant Centers: Thousands of hospitals globally
• Clinical Publications: 2,000+ peer-reviewed papers on Medtronic DBS

Research and Development

Current Research Focus

Adaptive DBS: Closed-loop systems that adjust stimulation based on neural signals

Directional Leads: Improved targeting to reduce side effects

Sensing Capabilities: Brain signal recording for personalized programming

MR Conditional: Full-body MRI compatibility

Partnerships

Medtronic collaborates with:

• Academic medical centers
• Neuroscience research institutions
• Other medical device companies

Cross-References

Related Companies

• Abbott Laboratories - Competitor (Infinity DBS)
• Boston Scientific - Competitor (Vercise DBS)
• NeuroPace - Related (RNS for epilepsy)

Related Disease Pages

• [Parkinson's Disease](/diseases/parkinsons-disease)
• Essential Tremor
• Dystonia

Related Brain Regions

• Subthalamic Nucleus
• Thalamus
• Globus Pallidus

Related Proteins/Genes

• [Alpha-Synuclein](/proteins/alpha-synuclein) (SNCA)
• [LRRK2](/entities/lrrk2)
• Parkin (PRKN)
• PINK1
• [Cell Types Overview](/companies/overview)
• [Disease Overview](/companies/overview)

External Links

• Medtronic DBS Website
• Medtronic DBS Patient Information
• [Clinical Trials](/clinical-trials)

References

Unknown, Medtronic plc. Company Overview. Annual Report 2024 (2024)

[Deuschl et al., A randomized trial of deep-brain stimulation for Parkinson's disease. NEJM 2006;355:896-908 (2006)](https://pubmed.ncbi.nlm.nih.gov/16614075/)